Nature Communications (May 2024)

Astrocytic ALKBH5 in stress response contributes to depressive-like behaviors in mice

  • Fang Guo,
  • Jun Fan,
  • Jin-Ming Liu,
  • Peng-Li Kong,
  • Jing Ren,
  • Jia-Wen Mo,
  • Cheng-Lin Lu,
  • Qiu-Ling Zhong,
  • Liang-Yu Chen,
  • Hao-Tian Jiang,
  • Canyuan Zhang,
  • You-Lu Wen,
  • Ting-Ting Gu,
  • Shu-Ji Li,
  • Ying-Ying Fang,
  • Bing-Xing Pan,
  • Tian-Ming Gao,
  • Xiong Cao

DOI
https://doi.org/10.1038/s41467-024-48730-2
Journal volume & issue
Vol. 15, no. 1
pp. 1 – 19

Abstract

Read online

Abstract Epigenetic mechanisms bridge genetic and environmental factors that contribute to the pathogenesis of major depression disorder (MDD). However, the cellular specificity and sensitivity of environmental stress on brain epitranscriptomics and its impact on depression remain unclear. Here, we found that ALKBH5, an RNA demethylase of N6-methyladenosine (m6A), was increased in MDD patients’ blood and depression models. ALKBH5 in astrocytes was more sensitive to stress than that in neurons and endothelial cells. Selective deletion of ALKBH5 in astrocytes, but not in neurons and endothelial cells, produced antidepressant-like behaviors. Astrocytic ALKBH5 in the mPFC regulated depression-related behaviors bidirectionally. Meanwhile, ALKBH5 modulated glutamate transporter-1 (GLT-1) m6A modification and increased the expression of GLT-1 in astrocytes. ALKBH5 astrocyte-specific knockout preserved stress-induced disruption of glutamatergic synaptic transmission, neuronal atrophy and defective Ca2+ activity. Moreover, enhanced m6A modification with S-adenosylmethionine (SAMe) produced antidepressant-like effects. Our findings indicate that astrocytic epitranscriptomics contribute to depressive-like behaviors and that astrocytic ALKBH5 may be a therapeutic target for depression.